Faculty

Institution

Unit

Venue

Michael W. Bevers

Professor non-tenure track

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

The University of Texas MD Anderson Cancer Center

Michael W. Bevers is a Professor (non-tenure track) at The University of Texas MD Anderson Cancer Center. His research focuses on gynecologic oncology, specifically ovarian cancer management, low-grade serous carcinoma, and molecular cancer therapeutics. He has led pivotal clinical trials, including the Phase II GOG 3026 trial of ribociclib plus letrozole for recurrent low-grade serous ovarian cancer and the BOUQUET biomarker-directed platform study for rare epithelial ovarian cancers. He co-authored the NCCN Guidelines for ovarian cancer and contributed to the 21-year update of the Normal Risk Ovarian Screening Study. His work advances neoadjuvant chemotherapy strategies and targeted therapies in gynecologic cancers.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Michael W. Bevers

The University of Texas MD Anderson Cancer Center

Professor non-tenure track

You can click a keyword to filter the displayed items

oncology gynecologic oncology gynecology ovarian cancer gynecologic cancers cancer treatment radiation oncology cancer research cancer management cancer care surgical oncology surgery cancer biology cancer cells gynecological surgery oncogenes tumor biology obstetrics and gynaecology cervical cancer molecular cancer medicine tumor targeting clinical research medicinal research minimally invasive procedures clinical trials reproductive medicine cancer discovery endocrine-related cancers pharmacotherapy endocrine oncology intraoperative consultation anti-cancer agents laparoscopy breast oncology clinical guidance clinical endpoint phase ii trial urogynecology colorectal cancer obstetrics novel therapies cancer genomics metronomic chemotherapy cancer growth therapeutic efficacy high-risk cervical cancer endometrial carcinoma pelvic exenteration advanced ovarian cancer endometrial cancer reproductive health plastic surgery reconstructive microsurgery gastrointestinal surgery malignant disease lymphatic disease lymphatic system treatment options female urology pelvic floor dysfunction epidemiology of cancer cancer screening pelvic radiation para-aortic radiation recurrent endometrial carcinoma ovarian cancer cells reproductive function epithelial ovarian cancer borderline ovarian tumors phase ii study mtor inhibition radiation therapy side effects patient support concurrent chemotherapy

Notable Scholarly Works

Notable Federal Grants

Collaborators

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A Gog Partners Trial (Gog 3026). Journal of Clinical Oncology (2025)

gynecologic oncologyradiation oncologyribociclib plus letrozolegynecologygog 3026gynecologic cancerscancer managementcancer treatmentintraoperative consultationcancer careoncologygog partners trial

Nccn Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network (2024)

Joyce LiuAndrew BerchuckFloor J. BackesJoshua CohenRachel GrishamCharles A. LeathLainie MartinDaniela MateiDavid S. MillerSharon RobertsonLisa BarroilhetShitanshu UppalAndrea Wahner HendricksonDavid M. GershensonHeidi J. GrayArdeshir HakamAngela JainGottfried E. KonecnyJohn MoroneyElena RatnerJohn SchorgePremal H. ThakerTheresa L. WernerEmese ZsirosKian BehbakhtLee-May ChenMarie DeRosaEric L. EisenhauerGary LeiserowitzBabak LitkouhiMichael McHaleSanja Percac-LimaKerry RodabaughRoberto VargasFrankie JonesEmily KovachLisa HangSwathi RamakrishnanRonald D. AlvarezDeborah K. Armstrong

oncogenesvascular biologycancer registrationcolorectal cancerovarian cancergliomasimmunologycancer literacymolecular cancerlung cancerprostate cancercarcinogenesisgenitourinary cancersperineural invasionmolecular gastroenterologysystems biologyurologyleukemia

Normal Risk Ovarian Screening Study: 21-Year Update. Journal of Clinical Oncology (2024)

Chae Young HanKaren H. LuGwen CorriganAlexandra PerezSharlene D. KohringJoseph CelestinoDeepak BediEnrique BediaTherese BeversDavid BorutaMatthew CarlsonLaura HolmanLeroy LeedsCara MathewsGeorgia McCannRichard G. MooreMatthew SchlumbrechtBrian SlomovitzDan TobiasYvette Williams-BrownMichael W. BeversJinsong LiuTerrie G. GornetBeverly C. HandyZhen LuJacob S. BediaSteven J. SkatesRobert C. Bast

health policypublic healthcancer screeningtreatment and preventionclinical epidemiologyclinical researchhealth sciencesoncology

747Mo First Results From the Engot-Gyn2/Gog-3051/Bouquet Phase II Biomarker-Directed Platform Study: Cobimetinib (Cobi) or Atezolizumab (Atezo) + Bevacizumab (Bev) for Persistent/Recurrent Rare Epithelial Ovarian Cancer (Eoc). Annals of Oncology (2023)

oncogenesgynecologic oncologypathologycancer cellsmolecular cancergynecologygynecologic cancersfirst resultsclinical endpointovarian cancercancer treatmentcancer managementoncology

Carboplatin Dosing in the Treatment of Ovarian Cancer: An Nrg Oncology Group Study. Gynecologic Oncology (2023)

Aaron M. PraissAustin MillerJudith SmithStuart M. LichtmanMichael BookmanCarol AghajanianPaul SabbatiniFloor BackesDavid E. CohnPeter ArgentaMichael FriedlanderMichael J. GoodheartDavid G. MutchDavid M. GershensonKrishnansu S. TewariRobert M. WenhamAndrea E. Wahner HendricksonRoger B. LeeHeidi GrayAngeles Alvarez SecordLinda Van LeRoisin E. O'Cearbhaill

gynecologic oncologyradiation oncologycarboplatin dosingcancer treatmentpharmacologytherapeutic efficacyovarian cancerpharmacotherapycancer careoncologycancer biology

Data From Antitumor and Antivascular Effects of Ave8062 in Ovarian Carcinoma. (2023)

Tae Jin KimMurali RavooriCharles N. LandenAparna A. KamatLiz Y. HanChunhua LuYvonne G. LinWilliam M. MerrittNicholas JenningsWhitney A. SpannuthRobert LangleyDavid M. GershensonRobert L. ColemanVikas KundraAnil K. Sood

gynecologic oncologyoncogenespathologyradiation oncologytumor biologycancer cellsanti-cancer agentscohort studiesovarian carcinomareactive oxygen speciesmolecular cancergynecologyantivascular effectscancer discoverygynecologic cancerstumor microenvironmentovarian canceroncology

Gog 3026 a Phase II Trial of Letrozole + Ribociclib in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum: A Gog Foundation Study (001). Gynecologic Oncology (2023)

Brian SlomovitzWei DengJosh KillionS. John WerohaFloor BackesDavid MillerMeaghan TenneyTilley Jenkins VogelLee-may ChenMerry MarkhamHye Sook ChonRobert ColemanDavid Gershenson

gynecologic oncologygog foundation studygynecologyfallopian tubephase ii trialovarian cancerbaseline correctiononcologyobstetrics and gynaecology

NOW: Neoadjuvant Olaparib Window Trial in Patients With Newly Diagnosed Brca Mutant Ovarian Cancer (Lba 1). Gynecologic Oncology (2023)

gynecologic oncologyradiation oncologycancer caresurgical oncologymolecular cancergynecologylba 1cancer discoverygynecologic cancerscancer managementovarian cancercancer treatmentclinical trialsoncology

Supplementary Figure 2 From Antitumor and Antivascular Effects of Ave8062 in Ovarian Carcinoma. (2023)

gynecologic oncologyvascular biologypathologyradiation oncologyovarian carcinomareactive oxygen speciesgynecologyantivascular effectsovarian canceroncology

Uptake and Outcomes of Neoadjuvant Chemotherapy Among Us Patients With Less Common Epithelial Ovarian Carcinomas. JAMA Network Open (2023)

Koji MatsuoShinya MatsuzakiMichihide MaedaAlesandra R. RauKosuke YoshiharaRyo TamuraMuneaki ShimadaHiroko MachidaMikio MikamiMaximilian KlarLynda D. RomanJason D. WrightAnil K. SoodDavid M. Gershenson

gynecologic oncologyepidemiologyradiation oncologymedicinal researchneoadjuvant chemotherapyoutcomes researchcancer researchmedicinecancer managementovarian cancercancer treatmentcancer careoncology

1
2
3
4
5
13
10 / page

Michael W. Bevers

Professor non-tenure track

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Michael W. Bevers

The University of Texas MD Anderson Cancer Center

Professor non-tenure track

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

gynecologic oncologyradiation oncologyribociclib plus letrozolegynecologygog 3026gynecologic cancerscancer managementcancer treatmentintraoperative consultationcancer careoncologygog partners trial

Nccn Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network (2024)

Normal Risk Ovarian Screening Study: 21-Year Update. Journal of Clinical Oncology (2024)

health policypublic healthcancer screeningtreatment and preventionclinical epidemiologyclinical researchhealth sciencesoncology

oncogenesgynecologic oncologypathologycancer cellsmolecular cancergynecologygynecologic cancersfirst resultsclinical endpointovarian cancercancer treatmentcancer managementoncology

Carboplatin Dosing in the Treatment of Ovarian Cancer: An Nrg Oncology Group Study. Gynecologic Oncology (2023)

gynecologic oncologyradiation oncologycarboplatin dosingcancer treatmentpharmacologytherapeutic efficacyovarian cancerpharmacotherapycancer careoncologycancer biology

Data From Antitumor and Antivascular Effects of Ave8062 in Ovarian Carcinoma. (2023)

Brian SlomovitzWei DengJosh KillionS. John WerohaFloor BackesDavid MillerMeaghan TenneyTilley Jenkins VogelLee-may ChenMerry MarkhamHye Sook ChonRobert ColemanDavid Gershenson

gynecologic oncologygog foundation studygynecologyfallopian tubephase ii trialovarian cancerbaseline correctiononcologyobstetrics and gynaecology

NOW: Neoadjuvant Olaparib Window Trial in Patients With Newly Diagnosed Brca Mutant Ovarian Cancer (Lba 1). Gynecologic Oncology (2023)

Supplementary Figure 2 From Antitumor and Antivascular Effects of Ave8062 in Ovarian Carcinoma. (2023)

gynecologic oncologyvascular biologypathologyradiation oncologyovarian carcinomareactive oxygen speciesgynecologyantivascular effectsovarian canceroncology

Uptake and Outcomes of Neoadjuvant Chemotherapy Among Us Patients With Less Common Epithelial Ovarian Carcinomas. JAMA Network Open (2023)

gynecologic oncologyepidemiologyradiation oncologymedicinal researchneoadjuvant chemotherapyoutcomes researchcancer researchmedicinecancer managementovarian cancercancer treatmentcancer careoncology

1
2
3
4
5
13
10 / page